Search

Displaying results 541 - 550 of 3917 in total
  1. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. … [A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS

  2. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.

  3. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

    Categories: Histamine H1 Antagonists, Non-Sedating
  4. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).

  5. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

  6. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    [A177985] Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. … [T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia.

  7. Drug

    Castor oil

    go.drugbank.com/drugs/DB11113
    ApprovedNutraceuticalVet approved

    Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (Ricinus communis L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of DB02955, which represents up to 90% o...

    Products: OLIO DI RICINO MARCO VITI
  8. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other...

  9. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]

    Categories: Analgesics, Non-Narcotic
  10. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    [L10556] Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] that directly acts on the heart muscle, diltiazem displays an intermediate … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.